Abstract
The emergence and evolution of new immunological cancer therapies has sparked a rapidly growing interest in discovering novel pathways to treat cancer. Toward this aim, a novel series of pyrrolidine derivatives (compound 5) were identified as potent inhibitors of ERK1/2 with excellent kinase selectivity and dual mechanism of action but suffered from poor pharmacokinetics (PK). The challenge of PK was overcome by the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 7. Lead optimization through focused structure-activity relationship led to the discovery of a clinical candidate MK-8353 suitable for twice daily oral dosing as a potential new cancer therapeutic.
Original language | English |
---|---|
Pages (from-to) | 761-767 |
Number of pages | 7 |
Journal | ACS Medicinal Chemistry Letters |
Volume | 9 |
Issue number | 7 |
DOIs | |
State | Published - 12 Jul 2018 |
Keywords
- ERK inhibitor
- MAPK pathway
- MK-8353
- kinase selectivity
- lead optimization
- oncology